MCID: CLR003
MIFTS: 56

Clear Cell Adenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma

Aliases & Descriptions for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 12 14
Mesonephroma 12 42 69
Water-Clear Cell Adenocarcinoma 12 69
Adenocarcinoma, Clear Cell 42 69
Mesonephroid Clear Cell Carcinoma 12
Clear Cell Adenocarcinoma Nos 12
Water-Clear Cell Carcinoma 12
Adenocarcinoma Clear Cell 52
Mesonephroma, Malignant 12
Malignant Mesonephroma 12
Wolffian Duct Neoplasm 12
Mesonephric Tumor 69
Mesonephroma Nos 12

Classifications:



Summaries for Clear Cell Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to bladder clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Deubiquitination and Development ERBB-family signaling. The drugs Aldesleukin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and colon, and related phenotypes are Decreased viability in esophageal squamous lineage and cardiovascular system

Wikipedia : 71 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
id Related Disease Score Top Affiliating Genes
1 bladder clear cell adenocarcinoma 33.4 ESR1 TP53
2 ovarian clear cell adenocarcinoma 12.2
3 cervical clear cell adenocarcinoma 12.1
4 endometrial clear cell adenocarcinoma 12.1
5 clear cell adenocarcinoma of ovary 12.1
6 fallopian tube clear cell adenocarcinoma 12.1
7 urethra clear cell adenocarcinoma 12.0
8 uterine ligament clear cell adenocarcinoma 12.0
9 ampulla of vater clear cell adenocarcinoma 12.0
10 bile duct clear cell adenocarcinoma 12.0
11 bladder tubulo-cystic clear cell adenocarcinoma 12.0
12 bladder papillary clear cell adenocarcinoma 12.0
13 bladder diffuse clear cell adenocarcinoma 11.9
14 wolffian duct adenoma 11.0
15 multilocular cystic clear cell renal cell neoplasm of low malignant potential 10.9
16 adenocarcinoma 10.9
17 vaginitis 10.4
18 endometriosis 10.4
19 malt worker's lung 10.3 KLK3 TP53
20 mitochondrial neurogastrointestinal encephalopathy disease 10.3 SMAD4 TP53
21 urethritis 10.2
22 fallopian tube germ cell cancer 10.2 ARID1A HNF1B SMAD3
23 iris spindle cell melanoma 10.2 AMACR KLK3 SMAD4
24 familial hypopituitarism 10.2 SMAD4 TP53
25 x-linked leigh syndrome 10.2 ESR1 SMAD4
26 tmem70 defect 10.2 PAX8 TP53
27 steroid-induced glaucoma - borderline 10.2 KLK3 KRT20
28 splenic infarction 10.1 AMACR KLK3 TP53
29 perinatal jaundice due to hepatocellular damage 10.1 ARID1A ESR1 HNF1B
30 congenital bile acid synthesis defect 10.1 ESR1 KLK3 TP53
31 adult medulloblastoma 10.1 AMACR KLK3 TP53
32 necrobiosis lipoidica 10.1 ESR1 KLK3 TP53
33 acute necrotizing encephalitis 10.1 KLK3 SMAD2 SMAD3
34 neuroectodermal endocrine syndrome 10.1 SMAD2 SMAD3 SMAD4
35 extramedullary plasmacytoma 10.1 KLK3 KRT20
36 urethral diverticulum 10.1
37 small intestine leiomyoma 10.1 KRT20 TP53
38 clear cell hidradenoma 10.1 KRT20 TP53
39 nevoid hypermelanosis, linear and whorled 10.1 ESR1 KLK3 TP53
40 cervicitis 10.1
41 spiradenoma 10.1 KRT20 TP53
42 trachea squamous cell carcinoma 10.1 ARID1A ESR1 TP53
43 fuchs' heterochromic uveitis 10.1 AMACR KLK3 PAX8
44 villoglandular endometrial endometrioid adenocarcinoma 10.1 ESR1 TP53
45 congenital pulmonary airway malformation 10.1 HNF1B PAX2
46 rhizomelic chondrodysplasia punctata spectrum 10.1 HNF1B PAX2
47 cervix endometriosis 10.1 AMACR KRT20
48 subareolar duct papillomatosis 10.1 ESR1 PAX8
49 placental site trophoblastic tumor 10.1 KRT20 SMAD4 TP53
50 papillary transitional carcinoma 10.1 KLK3 KRT20 TP53

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.23 ARID1A ESR1 HNF1B KLK3 PAX8 SMAD3

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.23 ARID1A ESR1 PAX2 PAX8 PTHLH SMAD2
2 cellular MP:0005384 10.22 ARID1A ESR1 PAX2 PAX8 PTHLH SMAD2
3 endocrine/exocrine gland MP:0005379 10.22 ARID1A ESR1 HNF1B PAX2 PAX8 PTHLH
4 growth/size/body region MP:0005378 10.21 AMACR ARID1A ESR1 HNF1B PAX8 PTHLH
5 embryo MP:0005380 10.19 ESR1 HNF1B PAX2 PAX8 SMAD2 SMAD3
6 homeostasis/metabolism MP:0005376 10.19 AMACR ARID1A ESR1 HNF1B PAX8 PTHLH
7 mortality/aging MP:0010768 10.14 SMAD4 TP53 AMACR ARID1A ESR1 HNF1B
8 craniofacial MP:0005382 10.1 SMAD3 SMAD4 TP53 ARID1A PAX8 PTHLH
9 immune system MP:0005387 10.08 ARID1A ESR1 HNF1B PTHLH SMAD2 SMAD3
10 digestive/alimentary MP:0005381 10.02 ESR1 PTHLH SMAD2 SMAD3 SMAD4 TP53
11 liver/biliary system MP:0005370 9.98 SMAD3 SMAD4 TP53 AMACR ESR1 HNF1B
12 nervous system MP:0003631 9.97 ARID1A ESR1 PAX2 PAX8 PTHLH SMAD2
13 limbs/digits/tail MP:0005371 9.93 ESR1 PAX8 PTHLH SMAD3 SMAD4 TP53
14 renal/urinary system MP:0005367 9.86 ESR1 HNF1B PAX2 PAX8 PTHLH SMAD3
15 neoplasm MP:0002006 9.85 ARID1A ESR1 SMAD2 SMAD3 SMAD4 TP53
16 reproductive system MP:0005389 9.81 ARID1A ESR1 PAX2 PAX8 PTHLH SMAD2
17 skeleton MP:0005390 9.56 ARID1A ESR1 PAX8 PTHLH SMAD2 SMAD3
18 vision/eye MP:0005391 9.17 PAX8 PTHLH SMAD2 SMAD3 TP53 ARID1A

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 288)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
3
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
4
Axitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 319460-85-0 6450551
5
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
6 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
9 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
11 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
21
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
22
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
23
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
24
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
25
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
26
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
27
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
28
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
29
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
30
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
31
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
32
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
33
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
34
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
35
Sulfamethoxazole Approved Phase 3 723-46-6 5329
36
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
39
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
40
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
41
lanreotide Approved Phase 2, Phase 3 108736-35-2
42
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
43
Somatostatin Approved Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
44
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
45
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
46
Pancrelipase Approved Phase 2, Phase 3,Phase 1 53608-75-6
47
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
48
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
49
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
50
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314

Interventional clinical trials:

(show top 50) (show all 405)
id Name Status NCT ID Phase
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Recruiting NCT02570789 Phase 4
3 Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors Recruiting NCT02700568 Phase 4
4 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Recruiting NCT01521715 Phase 4
5 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Recruiting NCT02982954 Phase 4
6 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02596035 Phase 4
7 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4
8 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
9 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
10 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
11 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
12 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
13 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
14 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
15 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
16 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3
17 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3
18 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
19 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
20 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3
21 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
22 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
23 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
24 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
25 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
26 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
27 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
28 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3
29 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3
30 Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer Completed NCT00427713 Phase 3
31 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
32 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
33 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Completed NCT00678392 Phase 3
34 GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma Completed NCT00495846 Phase 2, Phase 3
35 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3
36 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
37 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
38 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
39 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3
40 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
41 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Recruiting NCT02883153 Phase 2, Phase 3
42 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Recruiting NCT02535351 Phase 3
43 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Recruiting NCT01575548 Phase 3
44 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Recruiting NCT03055013 Phase 3
45 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Recruiting NCT02928692 Phase 3
46 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3
47 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
48 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
49 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3
50 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Genetic Tests for Clear Cell Adenocarcinoma

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

39
Cervix, Ovary, Colon, Prostate, Kidney, Uterus, Tongue

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 405)
id Title Authors Year
1
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
2
A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )
2016
3
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )
2016
4
Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )
2016
5
Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )
2016
6
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
7
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )
2015
8
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )
2015
9
A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )
2015
10
Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )
2015
11
Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )
2015
12
Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )
2015
13
High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )
2015
14
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
15
Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )
2015
16
Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )
2015
17
Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )
2015
18
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )
2015
19
Primary clear cell adenocarcinoma of the colon: a case report and review. ( 25311456 )
2014
20
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. ( 24669262 )
2014
21
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )
2014
22
Immunohistochemical and molecular features of primary clear cell-adenocarcinoma of the rectum, as predictive factors for individualized therapy. ( 25178336 )
2014
23
A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )
2014
24
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. ( 24721826 )
2014
25
Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )
2014
26
Clear cell adenocarcinoma of the colon: a case report and review of the literature. ( 24716050 )
2014
27
Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. ( 25140553 )
2014
28
Clear Cell Adenocarcinoma Arising in an Adenomyoma of the Broad Ligament. ( 24942896 )
2014
29
Primary clear cell adenocarcinoma of the peritoneum presents as Sister Mary Joseph's nodule: a case report and literature review. ( 25556287 )
2014
30
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
31
Primary clear cell adenocarcinoma of the colon presenting as a huge extracolic mass: A case report. ( 25202428 )
2014
32
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )
2014
33
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
34
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
35
Clear Cell Adenocarcinoma of the Prostate: A Rare Oncologic Entity in a 42-Year-Old African American Man. ( 25217452 )
2014
36
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
37
Primary Urethral Clear-Cell Adenocarcinoma: Comprehensive Analysis by Surgical Pathology, Cytopathology, and Next-Generation Sequencing. ( 24389164 )
2014
38
Cervical clear cell adenocarcinoma infected with human papillomavirus type 18 in an adolescent. ( 23849091 )
2014
39
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. ( 24987918 )
2014
40
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )
2014
41
Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )
2014
42
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. ( 25275661 )
2014
43
Clear cell adenocarcinoma of the abdominal wall: a case report. ( 24937978 )
2014
44
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. ( 24504419 )
2014
45
Clear cell adenocarcinoma of the peritoneum: a case report and literature review. ( 25366349 )
2014
46
Primary clear cell adenocarcinoma arising from rectal endometriosis. ( 23362987 )
2013
47
Vaginal laparoscopically assisted radical trachelectomy in cervical clear cell adenocarcinoma. ( 24244219 )
2013
48
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. ( 24375438 )
2013
49
An autopsy case of clear cell adenocarcinoma of the urinary bladder. ( 22024991 )
2013
50
Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems. ( 23307189 )
2013

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF Clear cell adenocarcinoma

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 47)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 ESR1 SMAD2 SMAD3 SMAD4 TP53
2
Show member pathways
12.48 SMAD2 SMAD3 SMAD4 TP53
3
Show member pathways
12.41 HNF1B SMAD2 SMAD3 SMAD4
4 12.36 SMAD2 SMAD3 SMAD4 TP53
5
Show member pathways
12.31 HNF1B PTHLH SMAD2 SMAD3 SMAD4
6 12.28 SMAD2 SMAD3 SMAD4 TP53
7
Show member pathways
12.27 SMAD2 SMAD3 SMAD4 TP53
8
Show member pathways
12.26 SMAD2 SMAD3 SMAD4 TP53
9 12.13 PAX2 SMAD2 SMAD3 SMAD4
10
Show member pathways
12.11 ESR1 SMAD2 SMAD3 SMAD4
11 12.06 SMAD2 SMAD3 SMAD4
12 12.05 SMAD2 SMAD3 SMAD4 TP53
13 12.01 SMAD2 SMAD3 SMAD4
14 12.01 SMAD2 SMAD3 SMAD4
15
Show member pathways
12.01 SMAD2 SMAD3 SMAD4
16 12 ESR1 SMAD2 SMAD4 TP53
17
Show member pathways
11.94 SMAD2 SMAD3 SMAD4 TP53
18 11.92 SMAD3 SMAD4 TP53
19 11.9 SMAD2 SMAD3 SMAD4 TP53
20 11.88 SMAD3 SMAD4 TP53
21
Show member pathways
11.86 SMAD2 SMAD3 SMAD4
22 11.84 SMAD2 SMAD3 SMAD4
23
Show member pathways
11.81 SMAD2 SMAD3 SMAD4
24 11.8 KLK3 SMAD3 SMAD4
25 11.76 SMAD2 SMAD3 SMAD4
26 11.74 SMAD3 SMAD4 TP53
27
Show member pathways
11.71 SMAD2 SMAD3 SMAD4
28 11.7 KLK3 PAX8 SMAD2 SMAD3 SMAD4 TP53
29 11.68 SMAD2 SMAD3 SMAD4
30 11.67 SMAD2 SMAD3 SMAD4
31
Show member pathways
11.65 SMAD2 SMAD3 SMAD4
32 11.62 ESR1 SMAD2 SMAD3 SMAD4
33 11.59 SMAD2 SMAD3 SMAD4 TP53
34 11.54 SMAD2 SMAD3 SMAD4
35 11.48 SMAD3 SMAD4 TP53
36 11.48 SMAD2 SMAD3 SMAD4
37
Show member pathways
11.46 SMAD2 SMAD3 SMAD4
38 11.39 SMAD2 SMAD3 TP53
39 11.32 ESR1 SMAD4 TP53
40
Show member pathways
11.27 SMAD2 SMAD3 SMAD4
41 11.14 ESR1 SMAD2 SMAD3 SMAD4
42 11.11 SMAD2 SMAD3 SMAD4
43 11.02 SMAD3 SMAD4
44 10.94 SMAD2 SMAD3 SMAD4
45 10.89 PAX2 PAX8
46 10.71 SMAD2 SMAD3 SMAD4
47 10.59 SMAD2 SMAD3 SMAD4

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 9.67 HNF1B SMAD2 SMAD3 SMAD4
2 protein complex GO:0043234 9.63 ESR1 KLK3 PAX2 SMAD2 SMAD3 TP53
3 activin responsive factor complex GO:0032444 9.32 SMAD2 SMAD4
4 SMAD2-SMAD3 protein complex GO:0071144 9.26 SMAD2 SMAD3
5 SMAD protein complex GO:0071141 9.13 SMAD2 SMAD3 SMAD4
6 nuclear chromatin GO:0000790 9.1 ARID1A ESR1 SMAD2 SMAD3 SMAD4 TP53
7 nucleus GO:0005634 10.17 ARID1A ESR1 HNF1B KLK3 PAX2 PAX8
8 nucleoplasm GO:0005654 10.06 ARID1A ESR1 HNF1B PAX8 PTHLH SMAD2

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 HNF1B SMAD2 SMAD3 TP53
2 transcription from RNA polymerase II promoter GO:0006366 9.99 ESR1 PAX2 PAX8 SMAD2 SMAD4 TP53
3 protein deubiquitination GO:0016579 9.89 ESR1 SMAD2 SMAD3 SMAD4 TP53
4 negative regulation of cell growth GO:0030308 9.88 SMAD3 SMAD4 TP53
5 kidney development GO:0001822 9.86 HNF1B PAX8 SMAD4
6 anterior/posterior pattern specification GO:0009952 9.86 HNF1B SMAD2 SMAD4
7 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 SMAD2 SMAD3 SMAD4
8 SMAD protein signal transduction GO:0060395 9.83 SMAD2 SMAD3 SMAD4
9 branching involved in ureteric bud morphogenesis GO:0001658 9.79 PAX2 PAX8 SMAD4
10 positive regulation of epithelial to mesenchymal transition GO:0010718 9.77 SMAD2 SMAD3 SMAD4
11 developmental growth GO:0048589 9.76 SMAD2 SMAD3 SMAD4
12 embryonic pattern specification GO:0009880 9.72 SMAD2 SMAD3
13 thyroid gland development GO:0030878 9.71 PAX8 SMAD3
14 intracellular estrogen receptor signaling pathway GO:0030520 9.71 ARID1A ESR1
15 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.71 SMAD3 TP53
16 signal transduction involved in regulation of gene expression GO:0023019 9.71 SMAD2 SMAD3
17 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.71 PAX2 PAX8
18 osteoblast development GO:0002076 9.7 PTHLH SMAD3
19 urogenital system development GO:0001655 9.7 PAX2 PAX8
20 activin receptor signaling pathway GO:0032924 9.7 SMAD2 SMAD3
21 uterus development GO:0060065 9.69 ESR1 SMAD4
22 mesonephros development GO:0001823 9.68 PAX2 PAX8
23 embryonic foregut morphogenesis GO:0048617 9.68 SMAD2 SMAD3
24 primary miRNA processing GO:0031053 9.67 SMAD2 SMAD3
25 pericardium development GO:0060039 9.67 SMAD2 SMAD3
26 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.67 PAX2 PAX8
27 nodal signaling pathway GO:0038092 9.66 SMAD2 SMAD3
28 mesonephric tubule development GO:0072164 9.66 HNF1B PAX8
29 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.65 PAX2 PAX8
30 metanephric epithelium development GO:0072207 9.65 PAX2 PAX8
31 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.65 SMAD2 SMAD3 SMAD4
32 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.64 PAX2 PAX8
33 regulation of transforming growth factor beta2 production GO:0032909 9.64 SMAD3 SMAD4
34 metanephric nephron tubule formation GO:0072289 9.63 PAX2 PAX8
35 metanephric distal convoluted tubule development GO:0072221 9.63 PAX2 PAX8
36 gastrulation GO:0007369 9.62 ARID1A SMAD2 SMAD3 SMAD4
37 nephric duct formation GO:0072179 9.61 HNF1B PAX2
38 paraxial mesoderm morphogenesis GO:0048340 9.58 SMAD2 SMAD3
39 SMAD protein complex assembly GO:0007183 9.58 SMAD2 SMAD3 SMAD4
40 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.57 PAX2 PAX8
41 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.56 PAX2 PAX8
42 endoderm development GO:0007492 9.56 HNF1B SMAD2 SMAD3 SMAD4
43 positive regulation of metanephric DCT cell differentiation GO:2000594 9.55 PAX2 PAX8
44 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.54 PAX2 PAX8
45 pronephros development GO:0048793 9.54 HNF1B PAX2 PAX8
46 pronephric field specification GO:0039003 9.52 PAX2 PAX8
47 regulation of binding GO:0051098 9.33 SMAD2 SMAD3 SMAD4
48 positive regulation of transcription, DNA-templated GO:0045893 9.28 ARID1A ESR1 HNF1B PAX2 PAX8 SMAD2
49 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.13 HNF1B PAX2 PAX8
50 regulation of transcription, DNA-templated GO:0006355 10.26 ARID1A ESR1 HNF1B PAX2 PAX8 SMAD2

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.95 ESR1 HNF1B PAX8 SMAD3 SMAD4
2 protein heterodimerization activity GO:0046982 9.91 HNF1B SMAD2 SMAD3 SMAD4 TP53
3 DNA binding GO:0003677 9.91 ARID1A ESR1 HNF1B PAX2 PAX8 SMAD2
4 transcription factor activity, sequence-specific DNA binding GO:0003700 9.87 ESR1 HNF1B PAX8 SMAD2 SMAD3 SMAD4
5 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.84 ESR1 PAX8 SMAD2 SMAD4
6 chromatin binding GO:0003682 9.83 ESR1 SMAD2 SMAD3 SMAD4 TP53
7 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.8 ESR1 PAX8 SMAD2 SMAD3 SMAD4
8 transcription factor binding GO:0008134 9.77 ESR1 PAX2 SMAD2 SMAD3 TP53
9 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.76 HNF1B SMAD3 SMAD4 TP53
10 enhancer binding GO:0035326 9.58 SMAD2 SMAD3
11 co-SMAD binding GO:0070410 9.57 SMAD2 SMAD3
12 I-SMAD binding GO:0070411 9.56 SMAD2 SMAD4
13 primary miRNA binding GO:0070878 9.52 SMAD2 SMAD3
14 transcription factor activity, protein binding GO:0000988 9.49 SMAD3 SMAD4
15 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.48 SMAD2 SMAD3
16 R-SMAD binding GO:0070412 9.33 SMAD2 SMAD3 SMAD4
17 core promoter proximal region sequence-specific DNA binding GO:0000987 9.13 PAX2 SMAD3 SMAD4
18 transcription regulatory region DNA binding GO:0044212 9.1 HNF1B PAX2 PAX8 SMAD3 SMAD4 TP53

Sources for Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....